

# 11<sup>th</sup> Canadian Kidney Cancer Forum

Friday, October 16, 2020

Virtual Meeting held in Eastern Time (ET)

## KCRNC Chair

### Anil Kapoor

St. Joseph's Healthcare, Hamilton, ON

## Program Co-chairs

### Christina Canil

The Ottawa Hospital, Ottawa, ON

### Frédéric Pouliot

CHU de Québec, Québec City, QC

## SPEAKERS

### Michael Atkins

Georgetown University Hospital, Washington, DC

### William Chu

Sunnybrook Health Sciences Centre, Toronto, ON

### Tony Finelli

University Health Network, Toronto, ON

### Danny Heng

Tom Baker Cancer Centre, Calgary, AB

### Michael Jewett

University of Toronto, Toronto, ON

### John Kachura

University of Toronto, Toronto, ON

### Aly-Khan Lalani

McMaster University, Hamilton, ON

### Alan So

Vancouver Prostate Centre, Vancouver, BC

### Brian Shuch

Ronald Reagan UCLA Medical Center UCLA Health, LA, CA

### Sandra Turcotte

Atlantic Canada Research Institute, Moncton, NB

### Lily Wu

Ronald Reagan UCLA Medical Center UCLA Health, LA, CA

**KCRNC** KIDNEY CANCER RESEARCH  
NETWORK OF CANADA  
**RRCRC** RÉSEAU DE RECHERCHE SUR LE  
CANCER DU REIN DU CANADA



VIRTUAL MEETING



## AGENDA


- 1100 - 1105 **General Welcome**  
Tiffany Pizioli, CEO, Canadian Urological Association
- 1105 - 1130 **Welcome & Update on Ongoing Canadian Research Projects**  
Anil Kapoor, Meeting Chair  
Additional Presenters: Kristen McAlpine, Maryam Soleimani, Rola Saleeb
- 1130 - 1155 **Keynote: Mechanism of Metastasis and Future Targets For Clinical Research**  
Keynote: **Lily Wu**  
Moderator: Frédéric Pouliot
- 1155 - 1200 Discussion, Q&A
- 1200 - 1245 **Showcase of Canadian Basic Science Research**  
Moderators: **Lily Wu**, Frédéric Pouliot
- 1200 - 1215 Alan So  
1215 - 1220 Discussion, Q&A  
1220 - 1235 Sandra Turcotte  
1235 - 1240 Discussion, Q&A  
1240 - 1245 General Discussion
- 1245 - 1330 **2020 Soper Grant Research Competition Finalist Presentations**  
Moderator: Michael Jewett
- 1330 - 1345 **Health Break**
- 1345 - 1415 **Keynote: 2020 Metastatic RCC Update**  
Keynote: **Michael Atkins**  
Moderator: Danny Heng
- 1415 - 1420 Discussion, Q&A
- 1420 - 1445 **Canadian Perspective on 2020 Updates**  
General Discussion, Q&A  
Danny Heng, Christina Canil
- 1445 - 1500 **Health Break**
- 1500 - 1525 **Keynote: Surgical Management of Complex VHL RCC Cases**  
Keynote **Brian Shuch**  
Moderator: Tony Finelli
- 1525 - 1530 Discussion, Q&A
- 1530 - 1615 **Case and Panel Discussion of Complex RCC Cases**  
Moderator: Frédéric Pouliot  
Panelists: **Brian Shuch**, William Chu, Tony Finelli, John Kachura
- 1615 - 1645 **Canadian Clinical Trials: Current and Future**  
Aly-Khan Lalani  
Additional Presenters: Patrick Richard, William Chu, Linda Trihn
- 1645 - 1700 **Wrap-Up and Awarding 2020 Soper Grants**  
Anil Kapoor, Christine Collins
- 1700 **End of Main Session**



This event has been reviewed and approved by the Canadian Urological Association (CUA) as a Section 1 Group Learning Event, as defined by the Maintenance and Certification Program of the Royal College of Physicians and Surgeons, for a maximum of 5.25 hours.

[cua.org](http://cua.org)

# KEYNOTE SPEAKERS



## Michael B. Atkins, MD

Dr. Atkins was recently appointed Deputy Director of the Georgetown-Lombardi Comprehensive Cancer Center in Washington, DC, and Professor of Oncology and Medicine (Hematology/Oncology) at Georgetown University School of Medicine. Prior to his move to Georgetown, he was Deputy Chief of the Division of Hematology/Oncology, Director of the Cancer Clinical Trials Office, Director of the Cutaneous Oncology Program, and Director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center (BIDMC). In addition, he was the leader of the Kidney Cancer Program at the Dana-Farber/Harvard Cancer Center and Professor of Medicine at the Harvard Medical School. He served as Director of the DF/HCC Kidney Cancer Specialized Program of Research Excellence (SPORE) grant and co-principal investigator of the DF/HCC Skin Cancer SPORE since their inception in 2003 and 2001, respectively. Dr. Atkins completed his medical education at Tufts University School of Medicine, and postgraduate training at the Cancer Center at Tufts New England Medical Center Hospital. There he held several academic and hospital appointments, before joining the staff at BIDMC in 1997. Dr. Atkins' major research interests are cancer immunotherapy, treatment of melanoma and renal cell carcinoma, predictive markers for response to biologic therapy, and antiangiogenic and targeted therapies. His research work has been funded by the National Cancer Institute, various foundations, and several pharmaceutical companies. He has been on the editorial boards of several journals, including **Cancer**, **Journal of Translational Medicine**, **Kidney Cancer Journal**, **Journal of Clinical Oncology**, and is Associate Editor to **Journal of Immunotherapy**. He has authored over 300 peer-reviewed original research articles, book chapters, review articles, and editorials, and edited three books. Dr. Atkins also serves on the advisory boards of the Melanoma Foundation of New England, the Melanoma Research Foundation Breakthrough Consortium, and the Kidney Cancer Association; has served on program committees for ASCO and AACR; and is past president of the International Society for Biological Therapy of Cancer.

---



## Brian Shuch, MD

Dr. Shuch is the Director of the Kidney Cancer Program and the Alvin & Carrie Meinhardt Endowed Chair in Kidney Cancer Research. He completed his urology training at UCLA followed by a urologic oncology fellowship at the National Cancer Institute. He is an accomplished surgeon (open/laparoscopic/robotic surgery and percutaneous ablations) and clinical/translational researcher. He serves in leadership positions within various kidney cancer research organizations, such as SWOG and the Society of Urologic Oncology. He is recognized as an expert in the genetics of kidney cancer and runs a translational research program with over 140 peer-reviewed publications, including primary research published in prestigious journals such as **Nature**, **Nature Genetics**, **Proceedings of the National Academy of Sciences**, **Journal of Clinical Oncology**, and **Clinical Cancer Research**. He is one of the few clinicians to bring bench science to the bedside in an upcoming therapeutic clinical trial for metastatic kidney cancer.

Previously, Dr. Shuch was at Yale from 2013-2018 as an Associate Professor of Urology and Diagnostic Radiology, Director of the Genitourinary Cancer Genetics and Prevention Program, and the Director of the Genitourinary Biospecimen Repository

---



## Lily Wu, MD

Dr. Wu is a biomedical research scientist focused on developing cancer-targeted therapy. She has been a faculty member of the Department of Urology since 1998, and she holds joint appointments in the Department of Molecular & Medical Pharmacology and the Department of Pediatrics. Dr. Wu earned her BSc degrees in biochemistry and physiology at University of California, Berkeley in 1982. She graduated in 1989 as a member of the inaugural class of medical scientist training program (MD/PhD program) at UCLA. Her early research on gene-based cancer therapy was initiated with the support of a Howard Hughes Medical Institute Postdoctoral Fellowship for Physicians in 1994. Her education training ranges from clinical disciplines of pediatrics and hematology/oncology to molecular and cellular fields, such as adenovirus biology, transcription regulation, and gene therapy. Dr. Wu has a long-standing interest to solve the problem of cancer metastasis. This interest was inspired by a new metastatic kidney cancer model that her group recently developed. Besides her research endeavors, a major part of her effort involves mentoring students at all levels, from undergraduates, graduate, postdoctoral fellows to clinical residents. Her diverse background creates a fertile ground for the interdisciplinary approaches she has taken in her research. Her main goal is to deliver safe, effective, and targeted treatment to cancer patients.

# KCRNC CHAIR



## Anil Kapoor, MD, FRCSC

Dr. Kapoor is currently Professor of Surgery (Urology & Oncology) at McMaster University/ St. Joseph's Hospital in Hamilton, Ontario, Canada. He obtained his MD from Dalhousie University. He is a Fellow of the Royal College of Physicians and Surgeons of Canada and a Diplomate of American Board of Urology. He is certified by the American Society of Transplant Surgeons, having obtained postgraduate training from the Cleveland Clinic Foundation in renal transplantation, reno-vascular surgery, and GU oncology.

Dr. Kapoor is also Head of the Genito-Urinary Oncology program at the Juravinski Cancer Centre, Co-Chair of the NCIC Kidney Cancer Disease Group, and Chair of the Kidney Cancer Research Network of Canada (KCRNC). He is also past Chair of the Medical Advisory Board (MAB) of Kidney Cancer Canada (KCC). He has published over 250 peer-reviewed papers, five book chapters, and over 300 abstracts in the fields of genitourinary oncology (prostate cancer and kidney cancer), kidney transplantation, and urologic laparoscopy. He is currently Head of the Clinical Trials Group at the McMaster Institute of Urology (MIU) and established the Kidney Cancer Centre at McMaster University in 2009, and the Prostate Cancer Basic Science Research Collaborative in 2015.

## MEETING CO-CHAIRS



## Christina Canil, MD, FRCPC

Dr. Canil a staff Medical Oncologist at the Ottawa Hospital Cancer Centre and an Assistant Professor in the Faculty of Medicine at the University of Ottawa. She completed medical school and her internal medicine residency at the University of Toronto and her medical oncology residency at McMaster University in Hamilton . She went on to complete a two-year clinical research fellowship at the Princess Margaret Hospital in Toronto, with a focus on genitourinary (GU) cancers. Her clinical research interests include drug development and survivorship in GU cancers. She is a member of the Cancer Care Ontario Program in Evidence-Based Care GU Cancer Disease Site Group. Dr. Canil is a co-lead with Dr. Jennifer Jones for the survivorship initiative of the Kidney Cancer Research Network of Canada.



## Frédéric Pouliot, MD, FRCSC

Since 2010, Dr. Pouliot has practiced as a urologist-oncologist in the Quebec City University Hospital Center. He is also an Associate Professor in Laval University's Department of Surgery. He oversees the CHU de Québec multidisciplinary clinic in castration-resistant prostate cancer. Dr. Pouliot obtained doctorates in medicine and in physiology-endocrinology from Laval University. After completing a residency in urology, he did a post-doctoral fellowship in urologic oncology and molecular imaging at the University of California, Los Angeles (UCLA). He is on the executive of CKCis and has contributed on several RCC clinical trials. In 2014, he was the recipient of the Prostate Cancer Canada/Movember Rising Star Award. He is also the recipient of the FRQS Clinical Research Scholars Junior 1 and 2 and Senior. His clinical and preclinical research interests include the detection and characterization of high-risk, advanced, and metastatic prostate cancers using transcriptional amplification systems or positron emission tomography with tracers such as fluoro-deoxyglucose or PSMA ligands (PyL, MP-1404). He is also involved in the development of new radioligand therapeutics.

## SPONSORED BY

### PLATINUM SPONSORS



### SILVER SPONSORS

